- Home
- IBRX vs PI Comparison
IBRX vs PI Comparison
Compare IBRX & PI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PI
- Stock Information
- Founded
- IBRX 2014
- PI 2000
- Country
- IBRX United States
- PI United States
- Employees
- IBRX N/A
- PI N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PI Industrial Machinery/Components
- Sector
- IBRX Health Care
- PI Technology
- Exchange
- IBRX Nasdaq
- PI Nasdaq
- Market Cap
- IBRX 2.4B
- PI 2.7B
- IPO Year
- IBRX N/A
- PI 2016
- Fundamental
- Price
- IBRX $2.96
- PI $88.40
- Analyst Decision
- IBRX Strong Buy
- PI Strong Buy
- Analyst Count
- IBRX 5
- PI 8
- Target Price
- IBRX $11.35
- PI $175.00
- AVG Volume (30 Days)
- IBRX 5.6M
- PI 498.5K
- Earning Date
- IBRX 03-03-2025
- PI 04-23-2025
- Dividend Yield
- IBRX N/A
- PI N/A
- EPS Growth
- IBRX N/A
- PI N/A
- EPS
- IBRX N/A
- PI 1.39
- Revenue
- IBRX $14,745,000.00
- PI $366,087,000.00
- Revenue This Year
- IBRX $621.53
- PI N/A
- Revenue Next Year
- IBRX $163.57
- PI $26.77
- P/E Ratio
- IBRX N/A
- PI $63.60
- Revenue Growth
- IBRX 2270.58
- PI 19.04
- 52 Week Low
- IBRX $2.28
- PI $83.58
- 52 Week High
- IBRX $10.53
- PI $239.88
- Technical
- Relative Strength Index (RSI)
- IBRX 49.28
- PI 37.88
- Support Level
- IBRX $2.69
- PI $89.50
- Resistance Level
- IBRX $3.47
- PI $93.28
- Average True Range (ATR)
- IBRX 0.23
- PI 3.84
- MACD
- IBRX 0.04
- PI 0.89
- Stochastic Oscillator
- IBRX 35.44
- PI 39.21
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PI Impinj Inc.
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.